EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The RORγt ligand-binding domain controls the pathogenicity of IL-17A+ T cells differently in autoimmune diseases of the skin and CNS

Keisuke Miyako, Toshio Kanno, Takeru Endo, Souta Yoshida, Yukie Iwao, Keiko Nakano, Arisa Ito, Satoru Yokoyama, Hikari K Asou, Kazuko Yamada, Takaharu Kimura, Manabu Nakayama und 2 weitere

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.116700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Keisuke Miyako und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu…. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Interleukin-17, Th17 Cells, Skin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Uehara Memorial Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transcription factor RORγt orchestrates Th17 lineage differentiation, thymic T cell development, and the pathogenesis of several autoimmune disorders. Lipid ligands are required for appropriate regulation of RORγt activity, but it is unclear to what extent lipid recognition controls RORγt function in vivo. Here, we show that the mutation of RORγt alanine-304 in the ligand-binding domain (LBD) to isoleucine (A304I) abrogates lipid-dependent Th17 differentiation and selectively ameliorates γδT17 cell-mediated psoriatic skin inflammation. In contrast, there is no improvement in experimental autoimmune encephalomyelitis in RORγtA304I mice. Consistent with this, the expression of genes characteristic of Th17 cells decreases in RORγtA304I mice, along with a compensatory increase of genes characteristic of Th1-like Th17 cells with pathogenic signatures. Thus, RORγt alanine-304 in the LBD is indispensable for generating γδT17 and conventional Th17 cells and for the suppression of the Th1-like Th17 pathogenic population, which decouples the pathogenicity of skin and CNS autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 1, Group F, Member 3Interleukin-17Th17 CellsSkinAutoimmune DiseasesCentral Nervous SystemAnimalsMiceEncephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLCell DifferentiationPsoriasisLigandsHumans

Stichwörter der Autor:innen

CP: ImmunologyEAERORγtTh17autoimmunitylipid ligandspsoriasisγδT17

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Interleukin-17Ligands

Autor:innen und Institutionen

  • Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan; Department of Applied Genomics, Kazusa DNA Re…
  • Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan.
  • Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan; Department of Pediatrics, Graduate School of…
  • Department of Applied Genomics, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan.
  • Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kazusa DNA Research Institute, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 292-0818, Japan; Department of Omics Medicine, Graduate School…

Förderung

  • Japan Agency for Medical Research and Development
  • Uehara Memorial Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Japan Science and Technology Agency
  • Ono Pharmaceutical
  • Shionogi Infectious Disease Research Promotion Foundation
  • Chemo-Sero-Therapeutic Research Institute
  • Ono Medical Research Foundation

Zitieren

APA

Miyako, K., Kanno, T., Endo, T., Yoshida, S., Iwao, Y., Nakano, K., Ito, A., Yokoyama, S., Asou, H. K., Yamada, K., Kimura, T., Nakayama, M., Ohara, O., & Endo, Y. (2025). The RORγt ligand-binding domain controls the pathogenicity of IL-17A+ T cells differently in autoimmune diseases of the skin and CNS. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116700

Vancouver

Miyako K, Kanno T, Endo T, Yoshida S, Iwao Y, Nakano K, et al. The RORγt ligand-binding domain controls the pathogenicity of IL-17A+ T cells differently in autoimmune diseases of the skin and CNS. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116700

BibTeX
@article{Miyako2025,
  author = {Miyako, Keisuke and Kanno, Toshio and Endo, Takeru and Yoshida, Souta and Iwao, Yukie and Nakano, Keiko and Ito, Arisa and Yokoyama, Satoru and Asou, Hikari K and Yamada, Kazuko and Kimura, Takaharu and Nakayama, Manabu and Ohara, Osamu and Endo, Yusuke},
  title = {The RORγt ligand-binding domain controls the pathogenicity of IL-17A+ T cells differently in autoimmune diseases of the skin and CNS},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.116700}
}
Kostenlos starten →